Cargando…
Correction: Kim et al. Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy. Cells 2021, 10, 670
Autores principales: | Kim, Ji Woong, Cho, Yea Bin, Lee, Sukmook |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8153583/ https://www.ncbi.nlm.nih.gov/pubmed/34069315 http://dx.doi.org/10.3390/cells10051198 |
Ejemplares similares
-
Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy
por: Kim, Ji Woong, et al.
Publicado: (2021) -
Antibody-Based Targeting of Cell Surface GRP94 Specifically Inhibits Cetuximab-Resistant Colorectal Cancer Growth
por: Jeoung, Mee Hyun, et al.
Publicado: (2019) -
Clinicopathologic and Prognostic Association of GRP94 Expression in Colorectal Cancer with Synchronous and Metachronous Metastases
por: Yun, Sumi, et al.
Publicado: (2021) -
Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAF(V600E) melanoma
por: Sabbatino, F, et al.
Publicado: (2015) -
Differential requirement of GRP94 and GRP78 in mammary gland development
por: Zhu, Genyuan, et al.
Publicado: (2014)